Looking Ahead to 2021: Let’s Really Make 2021 the Year of the Patient

Author: Jennifer Bright, MPA, Executive Director, IVI The promise of a new year offers an opportunity to recall our best moments in 2020 (surely there are a few!) and get excited for what's ahead. For IVI, I've been thinking about the accomplishments not just in 2020, but in the three years since I joined this [...]

2020-12-23T11:29:46-05:00December 23rd, 2020|Blog|

PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates

IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates. The model is also designed to [...]

2021-03-23T18:51:39-04:00January 7th, 2020|News, Press|

PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors

As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases? In the brief, the authors discuss how the failure of ICER’s analysis to evaluate [...]

2021-03-23T18:52:28-04:00December 10th, 2019|News, Press|

IVI Submits Comments on ICER Draft Evidence Report on JAK Inhibitors for RA

IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI's comments raise a broader question about the relevance of the analysis to decision making. IVI writes [...]

2019-11-13T13:07:31-05:00November 13th, 2019|News, Viewpoints|

IVI Announces a Request for Proposal (RFP)

IVI is committed to exploring scientifically rigorous methods that improve the practice of value assessment in a collaborative, iterative environment. To that end, we are pleased to announce the call for research proposals that help us advance our mission and demonstrate the applicability of patient-defined factors of value. IVI welcomes proposals from individual researchers as [...]

2019-07-31T13:22:40-04:00May 16th, 2019|Business Development, News|

To Get Our Money’s Worth in Healthcare, We Need to Collaborate

In a commentary for Modern Healthcare, IVI Director of Scientific Communications, Mark Linthicum, emphasizes that the healthcare system needs to embrace collaboration to find consensus in the way we measure and pay for health care value. Read the full article here.

2018-01-22T22:29:16-05:00January 22nd, 2018|Viewpoints|
Go to Top